Cargando…
Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy
Nanotechnology-based photo-chemo combination therapy has been extensively investigated to improve therapeutic outcomes in anticancer treatment. Specifically, with the help of a singlet oxygen generated by the photosensitizer, the endocytosed nanoparticles are allowed to escape from the endosomal com...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630662/ https://www.ncbi.nlm.nih.gov/pubmed/31234389 http://dx.doi.org/10.3390/pharmaceutics11060293 |
_version_ | 1783435355121254400 |
---|---|
author | Lim, Chaemin Kang, Jin Kook Won, Woong Roeck Park, June Yong Han, Sang Myung Le, Thi ngoc Kim, Jae Chang Her, Jaewon Shin, Yuseon Oh, Kyung Taek |
author_facet | Lim, Chaemin Kang, Jin Kook Won, Woong Roeck Park, June Yong Han, Sang Myung Le, Thi ngoc Kim, Jae Chang Her, Jaewon Shin, Yuseon Oh, Kyung Taek |
author_sort | Lim, Chaemin |
collection | PubMed |
description | Nanotechnology-based photo-chemo combination therapy has been extensively investigated to improve therapeutic outcomes in anticancer treatment. Specifically, with the help of a singlet oxygen generated by the photosensitizer, the endocytosed nanoparticles are allowed to escape from the endosomal compartment, which is currently an obstacle in nanotechnology-based anticancer therapy. In this study, a liposomal complex system (Lipo (Pep, Ce6)), composed of a chlorin e6-conjugated di-block copolymer (PEG-PLL(-g-Ce6)) and a D-(KLAKLAK)(2) peptide loading liposome (Lipo (Pep)), was developed and evaluated for its anticancer activity. Due to the membrane lytic ability of the D-(KLAKLAK)(2) peptide and the membrane disruptive effect of the singlet oxygen generated from chlorin e6, Lipo (Pep, Ce6) accelerated the disruption of the endosomal compartment, and exhibited strong synergistic anticancer activity in vitro. The prepared liposomal complex system could potentially maximize the efficacy of the nanotechnology-based photo-chemo combination therapy, and can be regarded as a novel, versatile strategy in advanced tumor therapy. |
format | Online Article Text |
id | pubmed-6630662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66306622019-08-19 Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy Lim, Chaemin Kang, Jin Kook Won, Woong Roeck Park, June Yong Han, Sang Myung Le, Thi ngoc Kim, Jae Chang Her, Jaewon Shin, Yuseon Oh, Kyung Taek Pharmaceutics Article Nanotechnology-based photo-chemo combination therapy has been extensively investigated to improve therapeutic outcomes in anticancer treatment. Specifically, with the help of a singlet oxygen generated by the photosensitizer, the endocytosed nanoparticles are allowed to escape from the endosomal compartment, which is currently an obstacle in nanotechnology-based anticancer therapy. In this study, a liposomal complex system (Lipo (Pep, Ce6)), composed of a chlorin e6-conjugated di-block copolymer (PEG-PLL(-g-Ce6)) and a D-(KLAKLAK)(2) peptide loading liposome (Lipo (Pep)), was developed and evaluated for its anticancer activity. Due to the membrane lytic ability of the D-(KLAKLAK)(2) peptide and the membrane disruptive effect of the singlet oxygen generated from chlorin e6, Lipo (Pep, Ce6) accelerated the disruption of the endosomal compartment, and exhibited strong synergistic anticancer activity in vitro. The prepared liposomal complex system could potentially maximize the efficacy of the nanotechnology-based photo-chemo combination therapy, and can be regarded as a novel, versatile strategy in advanced tumor therapy. MDPI 2019-06-21 /pmc/articles/PMC6630662/ /pubmed/31234389 http://dx.doi.org/10.3390/pharmaceutics11060293 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lim, Chaemin Kang, Jin Kook Won, Woong Roeck Park, June Yong Han, Sang Myung Le, Thi ngoc Kim, Jae Chang Her, Jaewon Shin, Yuseon Oh, Kyung Taek Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title | Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title_full | Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title_fullStr | Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title_full_unstemmed | Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title_short | Co-delivery of D-(KLAKLAK)(2) Peptide and Chlorin e6 using a Liposomal Complex for Synergistic Cancer Therapy |
title_sort | co-delivery of d-(klaklak)(2) peptide and chlorin e6 using a liposomal complex for synergistic cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630662/ https://www.ncbi.nlm.nih.gov/pubmed/31234389 http://dx.doi.org/10.3390/pharmaceutics11060293 |
work_keys_str_mv | AT limchaemin codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT kangjinkook codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT wonwoongroeck codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT parkjuneyong codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT hansangmyung codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT lethingoc codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT kimjaechang codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT herjaewon codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT shinyuseon codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy AT ohkyungtaek codeliveryofdklaklak2peptideandchlorine6usingaliposomalcomplexforsynergisticcancertherapy |